Orion Porfolio Solutions LLC Cuts Stock Holdings in Pfizer Inc. $PFE

Orion Porfolio Solutions LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 33.3% in the third quarter, Holdings Channel.com reports. The firm owned 473,044 shares of the biopharmaceutical company’s stock after selling 236,206 shares during the quarter. Orion Porfolio Solutions LLC’s holdings in Pfizer were worth $12,053,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of PFE. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Pfizer in the third quarter valued at approximately $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer in the second quarter valued at $30,000. Darwin Wealth Management LLC purchased a new stake in shares of Pfizer during the 2nd quarter worth $32,000. Evelyn Partners Asset Management Ltd acquired a new position in shares of Pfizer during the 2nd quarter worth $33,000. Finally, True Wealth Design LLC increased its holdings in shares of Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Federal judge approved a settlement awarding Pfizer $29 million related to the SEC’s 2013 insider‑trading case involving SAC Capital, closing a long‑running legal dispute and delivering a modest one‑time cash gain. Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund
• Positive Sentiment: Argus Research upgraded PFE to Buy with a $35 target, highlighting encouraging progress in Pfizer’s GLP‑1 obesity program and its oncology pipeline — a bullish catalyst for longer‑term revenue growth expectations. Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline
• Positive Sentiment: Investor writeups note portfolio renewal progress and attractive dividend yield for patient investors, framing Pfizer as a value/dividend play while its pipeline rebuild continues. Pfizer’s Portfolio Renewal In Progress – High Yields For The Patient
• Neutral Sentiment: Some outlets note the stock is down modestly since the last earnings release and are asking whether it can rebound — a monitoring signal rather than fresh news. Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound?
• Neutral Sentiment: Telescope Innovations installed a second self‑driving lab at Pfizer — a partnership update that points to operational/automation improvements but is unlikely to move near‑term revenues. Telescope Innovations Installs Second Self-Driving Lab at Pfizer
• Neutral Sentiment: Valuation pieces note divergence between long‑term return expectations and DCF views, signaling mixed investor opinions on fair value and outlook. A Look At Pfizer (PFE) Valuation As Long Term Returns And DCF Views Diverge
• Negative Sentiment: Analysis highlights structural growth challenges — falling COVID revenues, upcoming patent expirations and pricing/IRA headwinds — that could pressure sales and margins if new launches don’t scale. Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations?
• Negative Sentiment: Opinion pieces warn of “obesity hype” and potential vaccine policy shocks that could create volatility around expectations for new GLP‑1 products and vaccine revenues. Pfizer: Obesity Hype And Vaccine Policy Shocks

Wall Street Analyst Weigh In

A number of analysts recently commented on PFE shares. Morgan Stanley decreased their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research note on Wednesday, February 4th. Citigroup began coverage on Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective for the company. HSBC reiterated a “buy” rating and set a $29.00 target price on shares of Pfizer in a research report on Wednesday, December 10th. Finally, Bank of America cut their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $28.05.

Pfizer Stock Performance

Pfizer stock opened at $26.63 on Friday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The company has a market capitalization of $151.43 billion, a price-to-earnings ratio of 19.58 and a beta of 0.47. The stock has a fifty day moving average of $26.26 and a two-hundred day moving average of $25.46. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.63 earnings per share. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.